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Background: Circulating tumor cells (CTCs) detection has previously been used for diagnosing gastric cancer.
However, the previous studies failed to make an agreement whether the detection of CTCs contributes to the
diagnosis of gastric cancer.
Methods: A systematic review and meta-analysis was performed to evaluate the overall accuracy of CTCs detection
for diagnosing gastric cancer. PubMed, Embase and the Wanfang database were searched in all languages
published up to Oct 2012. The pooled sensitivity (SEN), specificity (SPE), positive and negative likelihood ratios (PLR
and NLR, respectively), diagnostic odds ratio (DOR) and summary receiver operating characteristic (sROC) curve
were calculated to evaluate the overall test performance.
Results: Twenty studies were included in this systematic review and meta-analysis. The diagnostic value of CTCs
detection for the gastric cancer was calculated to evaluate the overall test performance. The summary estimates of
The pooled sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio were 0.42 (95%
confidence interval (CI), 0.21-0.67), 0.99 (95% CI, 0.96-1.00), 58.2 (95% CI, 9.8-345.9), 0.58 (95% CI, 0.38-0.89), and 100
(95% CI, 15–663), respectively. The summary receiver operating characteristic curve was 0.97 (95% CI, 0.95–0.98).
Deek’s funnel plot asymmetry test found no evidence of study publication bias in the current study (P = 0.49).
Conclusion: This systematic review suggests that CTCs detection alone cannot be recommended as a screening
test for gastric cancer. However, it might be used as a noninvasive method for the confirmation of the gastric
cancer diagnosis.
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Gastric cancer is the 4th most frequently diagnosed can-
cer and the second leading cause of cancer-related death
[1]. It was estimated that 989,000 new cases and 738,000
deaths had occurred worldwide in 2008 alone, which
accounted for 8 percent of the total new cases and 10
percent of the total deaths [2]. Globally, gastric cancer
rates were about twice as high in males as in females.
The highest gastric cancer incidence rates were reported
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reproduction in any medium, provided the orthe lowest rates in North America and most parts of
Africa [3].
Generally, the current routine of the diagnosis is based
on symptoms, signs, serum tests of tumor markers, radi-
ology, and pathology. Unfortunately, most patients have
advanced gastric cancer at the time of diagnosis [4]. The
more advanced the tumor is, the worse the prognosis [5].
The five-year survival rate for advanced gastric cancer pa-
tients is 3.1% (1,4 in survival of metastatic gastric cancer
significant of age, sex), while the 5-year survival of patients
with early gastric cancer is over 90% (3 in prognostic fac-
tors in advanced gastric cancer). Although great improve-
ments have been made recently in the treatment of gastric
cancer, the high incidence of metastasis and recurrenced. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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prove the clinical outcomes of patients with gastric cancer,
new methods and techniques were developed to facilitate
the diagnosis of this disease.
Circulating tumor cells (CTCs) were first found in the
peripheral blood of cancer patients in 1869 [7], and they
were defined as tumor cells originating from either
primary or metastatic tumors and circulating in the per-
ipheral blood [8,9]. During the initial phase of the
micrometastasis, CTCs are shed intermittently from the
solid tumors into the peripheral blood [10]. Then be-
cause of the blood mechanical shear forces, immune sur-
veillance, and so on, most of CTCs will die, while a few
remaining CTCs survive and then circulate successfully
in the bloodstream, and later develop into clinically un-
detectable micrometastatic foci, which potentially grow
into clinically apparent metastases [11].
During the past few decades, a variety of approaches
to detecting CTCs have been developed. Generally, all
the methods consist of two phases: enrichment or isola-
tion/detection. The former includes morphologic-based
isolation and immunological isolation, such as: isolation
by size of epithelial tumor cells (ISET) [12,13], density
gradient separation (Ficoll-Hypaque [14]), CTC-chip
[15], microvortex-generating herringbone-chip [16], and
so on. While the latter includes nucleic acid-based
methods (PCR) and cytometric-based methods (flow cy-
tometry) [17]. Besides, the CellSearch system, an enrich-
ment and detection system, is the only approach
approved by the US Food and Drug Administration
(FDA) [18].
CTCs are reported to have the potential in assisting
the diagnosis of gastric cancer [19,20], evaluating prog-
nosis [21,22], monitoring the response of anticancer
therapy and monitoring the early microstasis [4]. How-
ever, the current studies failed to reach an agreement in
whether the detection of CTCs has contributed to the
diagnosis of gastric cancer. So the diagnostic value of
CTCs detection in gastric cancer was evaluated by the
meta-analysis and systematic review.Methods
Literature search
This meta-analysis was conducted according to guidelines
for diagnostic meta-analysis [23,24]. PubMed, Embase and
the Wanfang database were searched in Oct 2012 using
the strategy of (circulating tumor cell OR circulating
tumor cells OR CTC or CTCs OR isolated/circulating/
disseminated tumor cells OR ITC) AND (Gastric cancer
or Gastric Neoplasms or Stomach Cancer) without time
or language restrictions. The references of the included
studies were also searched manually to identify add-
itional eligible studies.Inclusion and exclusion criteria
The inclusion criteria for this meta-analysis were: 1)
studies about the diagnosis of gastric cancer with CTCs
detection; 2) studies with raw data that true-positive,
false-positive, false-negative and true-negative could be
found or calculated; 3) studies with reference standard
for the diagnosis of gastric cancer; 4) studies with more
than 20 patients. Exclusion criteria were: 1) studies with
duplicate data reported in other studies; 2) studies that
were letters, editorials, case reports or case series.
Data extraction and quality assessment
The two investigators (Lanhua Tang, Shushan Zhao) in-
dependently reviewed the titles and abstracts of all the
records searched above, and excluded the reviews, edito-
rials, letters, case reports or case series, and studies
without direct link to the main subject. For records
which could not be evaluated through the titles and ab-
stracts, full texts were retrieved for detailed evaluation
according to the inclusion and exclusion criteria. Dis-
agreements were resolved by discussion with the senior
investigator (Meizuo Zhong). The reasons why studies
were excluded were listed.
Two reviewers independently extracted data from all the
eligible studies: 1) basic characteristics of studies including
name of the first author, year of the publication, country
of origin, markers of CTCs detection methods, mean/me-
dian age, diagnosis criteria of gastric cancer, tumor stage
distribution of patients, source of control; 2) methods of
studies including study design, methods of the inclusion of
patients and controls, methods of CTCs detection, the
blood volume, time and methods of sample collection;
3) outcomes including the number of patients with true or
false positive and true or false negative results, detection
SEN. If the data of the results were not directly reported,
they were calculated based on SEN and SPE or positive
and negative predictive value. Disagreements were re-
solved by discussion and consultation with the senior in-
vestigator (Meizuo Zhong).
Subsequently, the two independent authors evaluated
the quality of the studies by Quality Assessment of Diag-
nostic Accuracy Studies-2 (QUADAS-2) [25] and Stan-
dards for Reporting of Diagnostic Accuracy (STARD) [26].
Data analysis
This systematic review and meta-analysis about the diag-
nostic accuracy of CTCs detection in gastric cancer was
performed using Stata software (version 12.0, College
Station, TX) with the MIDAS and METANDI modules
and RevMan (version 5.1).
With regards to Stata software, continuity correction
was implemented by an addition of 1 to avoid the
trouble that the cells containing zero values might bring
to the analysis process. And when a study adopted
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the best SPE or the best SEN was used for the analysis
of the pooled diagnostic accuracy.
By using a bivariate regression approach, the summary
receiver operating characteristic (sROC) curve was
constructed. The area under the sROC curve was an al-
ternative global measure of test performance. The
pooled estimates of SEN and SPE were calculated as the
main outcome measures. Meanwhile, the summary posi-
tive and negative likelihood ratios (pooled PLR and
pooled NLR, respectively, defined as the ratio of the
probabilities that the CTCs detection will be positive/
negative in cases with gastric cancer versus those with-
out gastric cancer) were also calculated. The value of
pooled PLR higher than 10 indicate that the positive re-
sult of the given test is useful for the confirmation of
presence of gastric cancer, while the value of pooled
NLR lower than 0.1 indicate that the negative result is
useful for the exclusion of the disease [27]. As a single
indicator measure of the diagnostic test accuracy that
comprises a combination of SEN and SPE [28], the diag-
nostic odds ratio (DOR) describes the odds of positive
test results in patients with gastric cancer compared
with the odds of positive results in those without the
disease. It’s calculated as: DOR = PLR/NLR.
The between-study heterogeneity was evaluated by
Q test and I-square statistics. The former indicates
whether the heterogeneity is significant. An inconsistency
index of 0% and P value of 0.05 and more indicate no
observed heterogeneity, when I2 becomes higher, theFigure 1 Flow diagram of study selection process.heterogeneity becomes greater. And I2 values ≥50% indi-
cates substantial heterogeneity, in this circumstance, the
DerSimonian Laird method was applied for pooled ana-
lyses [29,30].
Furthermore, to explore the sources of between-study
heterogeneity, a meta-regression was used according to
the characteristics of the included studies. Subgroup
analyses were also performed.
Publication bias was studied too by a regression of
diagnostic log odds ratio against 1/sqn’t. A non-zero
slope coefficient suggestive of significant small study bias
(p value < 0.10) [31].Results
Literature search
The results of the literature research were presented in
Figure 1. The initial search yielded a total of 1496 poten-
tial relevant studies. After the review of titles and ab-
stracts, 1449 articles were excluded: 1202 articles had no
direct link with the main subject; 218 of them were
reviews, editorials or letters; and 29 were case reports or
case series. Then 47 full manuscripts were retrieved
for detailed evaluation. Finally, 20 studies [19-22,32-47]
including a conference abstract [35] were included
according to the inclusion and exclusion criteria. The
remaining 29 studies were excluded because of the lack
of sufficient data (n = 14), duplicate publications (n = 1),
without control group (n = 12), and studies less than 20
patients (n = 2).
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The main characteristics of the studies included in the
meta-analysis were shown in Table 1.
A total of 1030 patients and 668 controls were in-
cluded in this meta-analysis. The included studies were
mainly performed in Asia (China: 55%, Japan: 35%,
Korea: 5%), and the remaining one was conducted in
Italy [22]. There are 5 articles in Chinese (25%), and the
other 15 were in English. All but two studies [38,47] in-
cluded patients of I-IV stage, whereas Noh et al. [38] did
not included patients of stage II, and Zhou et al. [47]
did not report the tumor stage.
There were 15 of 20 (75%) studies having peripheral
blood samples collected before any treatments, while 3
[20,32,47] of 20 (15%) collected blood samples after the
treatments in partial patients and 2 [40,45] did not re-
port the time of sample collection. In order to avoid
contamination by epithelial cells, 8 studies (40%) col-
lected two consecutive blood samples, and only the sec-
ond tube was used for analysis with the first tube
discarded. Mean volume of the blood samples was 6.23
(range: 2–14) milliliter (ml) with 13 studies (65%)
collecting ≤7.5 ml blood samples.
As for CTCs enrichment, 4 (20%) studies used density
gradient separation (3 for Ficoll-Hypaque centrifugation
method), 5 (25%) studies applied the acid guanidium-
phenol-chloroform or (acid) guanidium thiocyanate-phenol
-chloroform method, 6 (30%) studies adopted the RNeasy
Mini Kits or QIAamp RNA blood Mini Kit extraction, 2
(10%) studies used immunomagnetic isolation, and 2 (10%)
studies used lymphocyte separation medium. There was 1
(5%) study that did not report the cell enrichment method.
Polymerase chain reaction (PCR) based methods were
applied in 17 (85%) of 20 studies to detect CTCs, among
which reverse transcription or real time polymerase
chain reaction (RT-PCR) was the most common method
(11 of 20), 3 used quantitative RT-PCR (qRT-PCR), 2
used multiplex RT-PCR, and 1 adopted Nested PCR. Be-
sides, there were 2 (10%) studies adopted immunological
methods, and 1 (5%) used the CellSearch system. The
most frequently used markers of PCR-based methods
were carcinoembryonic antigen (CEA, evaluated in 8 of
20 studies, 40%) and cytokeratin-19 (CK-19, evaluated in
8 of 20 studies, 40%) followed by cytokeratin-20 (CK-20,
evaluated in 5 of 20 studies, 25%), other markers were
EpCAM (10%), hTERT (10%), MUC1 (10%), c-Met (5%),
MAGE-1 (5%), Survivin (5%), VEGF (5%), MAGE-3
(5%), GFP (5%).
Assessment of study quality
Quality assessment was shown with a bar graph according
to the QUADAS-2 tool in Figure 2. 11 of 20 studies in this
meta-analysis fulfilled 18 or more of the 25 items in the
STARD (Additional file 1: Table S1).Diagnostic accuracy of CTCs detection
The pooled SEN and SPE of CTC for the diagnosis of
gastric cancer were 0.42 (95% confidence interval (CI),
0.21-0.67) and 0.99 (95% CI, 0.96-1.00) respectively
(Figure 3, Table 2), with significant heterogeneity (P < 0.01,
I2 = 95.54% and P < 0.01, I2 = 83.67%). Additionally, the
pooled PLR was 58.2 (95% CI, 9.8-345.9) and the NLR was
0.58 (95% CI, 0.38-0.89) (Table 2). The DOR was 100
(95% CI, 15–663). Figure 4 presented the sROC curve
for the included studies. The area under the curve
(AUC) was 0.97 (95% CI 0.95–0.98).
The proportion of heterogeneity likely due to thresh-
old effect was 19%, which meant a slight influence of a
diagnostic threshold effect. To explore other potential
heterogeneities, meta-regression and subgroup meta-
analysis were performed (Figure 5). Overall, the test per-
formances varied by patient population, study design
and study quality. The pooled SPE was lower with some
covariates, such as study size greater than 30 (P < 0.001),
adequate description of study subjects (P < 0.001), sat-
isfactory reporting of results (P < 0.001) and broad
spectrum of disease (P < 0.01).
As shown in the Fagan plot (Figure 6), with a pre-test
probability of gastric cancer of 61% in this meta-analysis,
the posttest probability of gastric cancer, given a negative
CTCs detection result, was 48%, while 99% with a posi-
tive result.
According to the Deek’s funnel plot asymmetry test,
the P value was 0.49 for the slope coefficient, which
showed there was not a significant publication bias
(Figure 7). The likelihood ratio scattergram (Figure 8)
showing summary point of likelihood ratios obtained as
functions of mean SEN and specificity in the right upper
quadrant suggested that the CTCs detection was useful
for the confirmation of presence of gastric cancer (when
positive) but not for its exclusion (when negative) [23].
The predictive values and probability modifying plot was
shown in Additional file 1: Figure S2.
The pooled SEN, SPE, PLR, NLR, DOR and the AUC
mentioned above were summarized in Table 2.
Diagnostic accuracy of CTCs detection in different
markers (subgroup analysis)
8 studies reported data about CK-19 [19,21,22,33,36,
37,43,45], 5 about CK-20 [19,33,36,37,39], and 8 about
CEA [19,22,33,34,38,43,44,46]. There were no significant
differences between the three biomarkers (Figure 9,
Additional file 1: Figure S3).
Diagnostic accuracy of CTCs detection in different phases
(subgroup analysis)
10 studies [19-21,34,35,37,38,41,43,44] reported data
about patients with stage I to III gastric cancer, and
stage IV. Figure 10 and Additional file 1: Figure S4
























Aihara 1997 Japan Keratin
19
0/49 0/50 0 0 49 50 NR NR I-IV No UICC RT-PCR
Bertazza 2009 Italy Survivin 69/70 0/20 69 0 1 20 68(28–90)† Yes I-IV Yes UICC qRT-PCR
CK19 68/70 0/20 68 0 2 20
CEA 30/70 0/20 30 0 40 20
VEGF 27/70 0/20 27 0 43 20
Cui 2011 China piR-651 66/93 6/32 66 6 27 26 preoperative:60 ± 17;
postoperative:63 ± 14
Yes I-IV Np National Comprehensive Cancer
Network clinical practice guideline of
oncology
qRT-PCR
piR-823 75/93 6/32 75 6 18 26
Hiraiwa 2008 Japan EpCAM 17/41 0/41 17 0 24 41 NR Yes I-IV Yes AJCC Immunological
Ikeguchi 2005 Japan CEA 0/59 0/15 0 0 59 15 66.3(26–86) Yes I-IV Yes Japanese Classification of Gastric
Carcinoma
RT-PCR
Ikeguchi 2003 Japan CEA 1/55 0/40 1 0 54 40 65.4 Yes I-IV No Japanese Classification of Gastric
Carcinoma
RT-PCR
CK19 0/55 0/40 0 0 55 40
CK20 15/55 2/40 15 2 40 38
Ito 2010 Japan GFP 27/27 0/80 27 0 0 80 56.1(39–76) Yes I-IV No AJCC Immunological
Koga 2008 Japan CK19 8/69 0/14 8 0 61 14 65.7 Yes I-IV No Japanese Classification of Gastric
Carcinoma
qRT-PCR
CK20 10/69 0/14 10 0 59 14
Majima 2000 Japan CK19 5/52 0/14 5 0 47 14 NR NR I-IV Yes Creteria of the UICC RT-PCR
CK20 5/52 1/14 5 1 47 13
Noh 1999 Korea CEA 16/35 0/9 16 0 19 9 54.5(26–71) Yes I/III/IV No AJCC RT-PCR
Qiao 2007 China CK20 9/40 0/20 9 0 31 20 62.2 Yes No NR RT-PCR
Ren 2011 China EpCAM 20/33 0/60 20 0 13 60 NR Yes I-IV No AJCC Immunological
Uen 2006 China c-Met 32/52 2/36 32 2 20 34 60.0(34–84) Yes I-IV Yes AJCC RT-PCR
MUC1 37/52 3/36 37 3 15 33
Wang 2009 China MAGE-
1
19/40 0/20 19 0 21 20 55.7(27–77) Yes I-IV No AJCC RT-PCR
MAGE-
3
10/40 0/20 10 0 30 20
Wu 2006 China hTERT 52/64 14/80 52 14 12 66 60.5(36–84) Yes I-IV Yes AJCC RT-PCR
CK19 50/64 12/80 50 12 14 68
CEA 53/64 19/80 53 19 11 61

















Table 1 Main characteristics of studies included in the meta-analysis of the diagnostic accuracy of CTCs detection in gastric cancer (Continued)
Wu 2006 China hTERT 26/42 0/30 26 0 16 30 60.2(34–84) Yes I-IV Yes AJCC RT-PCR
CK19 29/42 1/30 29 1 13 29
CK20 26/42 1/30 26 1 16 29
CEA 33/42 0/30 33 0 9 30
Yang 2002 China CEA 24/40 1/34 24 1 16 33 51.2(38–76) Yes I-IV No AJCC RT-PCR
Yeh 1998 China CK19 7/34 0/33 7 0 27 33 57(31–81)† Yes I-IV Yes UICC RT-PCR
Zhang 2007 China CEA 4/45 0/13 4 0 41 13 60.5(42–78) Yes I-IV No UICC RT-PCR
Zhou 2010 China miR-
106a
43/90 3/27 43 3 47 24 male: 62.3;
female:59.2
Yes NR No UICC RT-PCR
MiR-17 47/90 2/27 47 2 43 25

















Figure 3 Forest plot showing study-specific (right-axis) and mean sensitivity and specificity with corresponding
heterogeneity statistics.
Figure 2 Overall quality assessment of included studies (QUADAS-2 tool): proportion of studies with low, high, or unclear risk of bias
(left), proportion of studies with low, high, or unclear concerns regarding applicability (right).
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Table 2 Pooled results of the meta-analysis of the diagnostic accuracy of CTCs detection in gastric cancer
Analysis scenario Sensitivity Specificity Positive LR Negative LR DOR Heterogeneity*
All studies 0.42 (0.21, 0.67) 0.99 (0.96, 1.00) 58.2 ( 9.8, 345.9) 0.58 (0.38, 0.89) 100 (15, 663) 98 (98, 99)
All studies without outliers 0.37 (0.16, 0.65) 0.99 (0.96, 1.00) 65.4 (8.4, 511.4) 0.63 (0.42, 0.96) 104 (11, 956) 94 (89, 99)
Subgroup: CEA 0.31 (0.10, 0.64) 0.94 (0.87, 0.98) 5.4 (2.1, 14.0) 0.73 (0.49, 1.09) 7 ( 2, 26) 98 (96, 99)
Subgroup: CK-19 0.27 (0.06, 0.67) 0.95 (0.90, 0.98) 5.4 (1.7, 16.4) 0.77 (0.50, 1.19) 7 (2, 31) 97 (96, 99)
Subgroup: CK-20 0.25 (0.13, 0.43) 0.95 (0.89, 0.98) 4.9 (1.6, 14.9) 0.79 (0.64, 0.98) 6 (2, 23) 0 (0, 100)
Subgroup: stage 1 0.22 (0.06, 0.56) 0.95 (0.89, 0.98) 4.3 (1.1, 17.7) 0.82 (0.59, 1.15) 5 (1, 29) 91 (83, 100)
Subgroup: stage 2 0.40 (0.14, 0.73) 0.96 (0.90, 0.98) 9.7 (4.5, 20.9) 0.62 (0.37, 1.07) 15 (5, 48) 93 (86, 99)
Subgroup: stage 3 0.46 (0.16, 0.80) 0.95 (0.90, 0.98) 9.4 (3.4, 25.9) 0.56 (0.28, 1.15) 17 (3, 83) 94 (89, 99)
Subgroup: stage 4 0.63 (0.43, 0.79) 0.97 (0.95, 0.98) 20.6 (11.2, 38.0) 0.38 (0.23, 0.64) 54 (21, 138) 71 (35,100)
Subgroup: stage 1-3 0.30 (0.09, 0.64) 0.96 (0.91, 0.98) 6.9 (2.2,21.3) 0.73 (0.48, 1.12) 9 (2, 42) 97 (95, 99)
Subgroup: PCR-based assay 0.39 (0.20, 0.60) 0.94 (0.90, 0.96) 6.1 (3.6, 10.4) 0.94 (0.90, 0.96) 9 (4, 21) 96 (95, 97)
Subgroup: immunological assay 0.82 (0.43, 1.00) 1.00 (0.98, 1.00) 74.5 (15.0,368.9) 0.335 (0.12-0.97) 340.9 (23.26,4996.7) 93 (88, 97)
Numbers in parentheses are 95% CIs. DOR diagnostic odds ratio, LR likelihood ratio.
* Inconsistency indexes are percentages.
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tients was higher than in stage I to III, more specifically,
the SEN was higher in more advanced stage than earlier
stage (Additional file 1: Figure S5 and S6) while the SPE
was almost on the same level.Figure 4 Summary ROC curve with confidence and prediction regions
correspondence between numbers and the studies can be found in ADiagnostic accuracy of CTCs detection in different
detection methods (subgroup analysis)
There are two main methods for CTCs detection which are
PCR-based assays both exploiting tissue and/or tumor spe-
cific antigens and immunological assays using monoclonalaround mean operating sensitivity and specificity point (The
dditional file 1: Table S2).
Figure 5 Forest plot of multiple univariable meta-regression and subgroup analyses for SEN and SPE.
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can also be divided into two major groups. One is the PCR-
based assay group [19,21,22,32-34,36-39,41-47] while the
other is immunological assay [20,35,40]. The pooled sensi-
tivity of two group were 0.35 (95% CI, 0.11-0.59), and 0.82
(95% CI, 0.43-1.00) respectively. And the heterogeneity
were P < 0.01, I2 = 95.9% and P < 0.01, I2 = 80.0%.Sensitivity analysis
Figure 11d showed two outlier studies [32,43]. After the
exclusion of these two studies, the I2 for heterogeneity
decreased from 99% to 94%, the SEN decreased from
0.42 to 0.37, PLR increased from 58.2 to 65.4, NLRincreased from 0.58 to 0.63, and DOR increased from
100 to 104, while SPE had minimal change (Table 2).
Discussion
Recently, the detection of circulating cancer cells in per-
ipheral blood has received growing enthusiasm in the
diagnosis of various cancers. However, the diagnostic
accuracy varied in different studies. There were several
meta-analyses about CTCs detection in cancers. In
Tsao’s meta-analysis [49], tyrosinase messenger RNA
was positive in 18% patients with stage I cutaneous mel-
anoma disease, 28% with stage II disease, 30% with stage
III disease, and 45% with stage IV disease. Specificities
were 1.00 in all but 1 study. A meta-analysis conducted
Figure 6 Fagan plot analysis to evaluate the clinical utility of
CTCs detection.
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tection in patients with lung cancer were 0.80 and
0.77, respectively. Msaouel and Koutsilieris et al. [11]
reported that the overall SEN and SPE of CTCs detec-
tion in patients with bladder and urothelial cancer
were 0.351 and 0.894, respectively. This current study
is the first meta-analysis focusing on the diagnostic
value of CTCs detection in peripheral blood of gastric
cancer patients.
In this meta-analysis, CTCs detection in peripheral
blood of patients with gastric cancer had limited diag-
nostic value, because it failed to identify more than half
of the patients (SEN is only 0.42). Compared with the
meta-analyses mentioned above [11,50], the SEN in gas-
tric cancer was higher than that in bladder and
urothelial caner, while lower than lung cancer. However,
the SPE was high (0.99). These indicated that CTCsdetection might not be qualified as screening test, but
useful in the confirmation of gastric cancer. The SPE in
gastric cancer was almost the same as in lung cancer,
while higher than that in bladder and urothelial cancer.
Thus, it can be concluded that the confirmative value of
CTCs detection in gastric cancer was lower than that in
lung cancer, but higher than that in bladder and
urothelial cancer. The pooled PLR was 58.2, which indi-
cated that CTCs detection can confirm this disease, be-
cause few patients would be falsely diagnosed as gastric
cancer with positive CTCs detection, whereas, patients
might still have gastric cancer even though the results
are negative because the NLR was only 0.58, which
meant CTCs detection couldn’t rule out the disease by
the negative results. It should be noted that the high
DOR (100) as well as the high AUC (0.97) reflecting an
overall high diagnostic accuracy by CTCs detection.
According to the likelihood ratio scattergram, the plot
showed that CTCs detection could be useful for the con-
firmation of presence of gastric cancer (when positive)
but not for its exclusion (when negative).
There are various kinds of PCR based markers used
in the detection of CTCs, and they can be divided into
two categories. One is expressed by almost all the
tumor cells originated form epithelial cells, such as epi-
thelial markers (cytokeratins (CK), epithelial cell adhe-
sion molecule (EpCAM), human epithelial antigen
(HEA)). The other is tumor cell-specific markers that
are expressed by a particular type of cancer, such as
CEA, a-Foetoprotein, Her2-neu, CA-IX and prostate
specific antigen (PSA) [17,51]. However, only 3 markers
were investigated in more than three studies in this
meta-analysis, so subgroup analyses were performed
targeting these 3 markers. The results showed that
these three markers had similar SEN and SPE, and
showed less significant advantage than pooled SEN and
SPE. On the other hand, we found that the diagnostic
SEN of CTCs detection was higher in more advanced
tumor stage. CTCs were released from the primary
tumor or metastasis, so it was reasonable to detect
them in stage IV patients more easily. It was reported
that the CTCs detection in malignant melanoma had
correlated with clinical stage and had been an inde-
pendent prognostic factor for the disease recurrence
[52,53]. Identifying small amounts of tumor cells by
CTCs detection could prove the presence of micro-
metastasis in peripheral blood, but hardly by other
technologies such as pathology and radiology. Thus, for
patients who had positive CTCs detection results, post-
operative adjuvant chemotherapy or radiotherapy was
highly recommended. This association indicated that
CTCs detection might be helpful in therapy of gastric
cancer, especially for those who were more likely to
have advanced cancer.
Figure 7 Funnel plot with superimposed regression line.
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http://www.biomedcentral.com/1471-2407/13/314An important consideration in this meta-analysis was
its limitations. First of all, as in other diagnostic test ac-
curacy reviews, the basic characteristics of included
studies were not coherent. The time of sample collection
was not consistent. If the samples were collected after
surgeries, the circulating cancer cells might be released
into the peripheral blood due to surgeries, which would
increase the SEN, whereas, if the samples were collected
after the chemotherapy, the CTCs in the peripheral
blood might be killed. Moreover, 12 studies didn’t collectFigure 8 Likelihood ratio scattergram.two consecutive blood samples to avoid contamination
by epithelial cells. And CTCs detection diagnostic accur-
acy might be higher in studies in which larger blood vol-
umes were collected. A conference abstract [35] was also
included, in which the basic characteristic was unclear
and the scores of QUADAS and STARD couldn’t be
obtained without full text. What’s more, according to
the meta-regression, the sample size less than 30 intro-
duced significant heterogeneity (P < 0.001). In addition,
as we known, the ideal method to detect CTCs should
Figure 9 Summary ROC plot of SEN and SPE of CK 19, Ck 20, and CEA based CTCs detections. (Dotted ellipses around the spots represent
the 95% CI around the summary estimates. The diamonds, rectangles and circles represent individual studies and size of the diamonds/
rectangles/circles is proportional to the number of patients included in the study).
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http://www.biomedcentral.com/1471-2407/13/314focus on the tumor cells directly, for example cytopa-
thology, not the surrogate markers indirectly linked to
tumor cells as studied in the included papers. However,
the concentration of CTCs in blood stream is low, as a
result, the isolation and detection of CTCs is not an
easy process [54]. So PCR-based assay both exploiting
tissue and/or tumor specific antigens and immuno-
logical assay using monoclonal antibodies were devel-
oped to detect CTCs indirectly. Different methods may
increase the heterogeneity in meta-analysis, so sub-
group analysis was conducted based on the method.
The pooled SEN of the two group had no statistically
significant difference (P = 0.10), and the heterogeneity
still existed in both group. What’s more, we performed
a subgroup analysis according to the published years.
We divided the PCR-based assay group into three
groups, which were 1997–2002 group, 2003–2007
group and 2008–2012 group. The pooled SEN of three
subgroups were 0.17 (95% CI, 0.04-0.52), 0.31 (95% CI,
0.08-0.71) and 0.67 (95% CI, 0.27-0.92), respectively
(Additional file 2: Figure S7, Additional file 3: Figure S8).
The SEN has a trend of increase with the development
of times. So we believe that with the development de-
tection technology, we may get an ideal conclusion
when updating this meta-analysis in the future.Apart from all the items mentioned above might con-
tribute to the significant inter-study heterogeneity, the
outlier studies could also introduce heterogeneity [55].
According to Figure 11, there were 2 outliers [32,43] in
this meta-analysis, after the exclusion of the two outliers,
the heterogeneity did not change much, which meant
there were other potential factors resulting in the signi-
ficant heterogeneity, for example, the differences in
CTCs enrichment and identification techniques and bio-
markers. In this meta-analysis, the diagnostic threshold
effect and publication bias didn’t introduce significant
heterogeneity. In order to explore other potential hetero-
geneities, meta-regression and subgroup meta-analysis
were performed, and heterogeneity was found in sample
size, description of study subjects, reporting of results
and spectrum of the diseases in control group. There-
fore, multi-center studies with standardized study de-
signs were needed to decrease inter-study heterogeneity.
To include all the eligible studies as many as possible
and diminish the language bias in this systematic review,
we didn’t apply any restrictions about the language when
we searched the database, such as PubMed, Embase.
Meanwhile we used Wanfang Database as a supplemen-
tary database to collect the non-English language publi-
cations. Despite this, there should be some other
Figure 11 Graphical depiction of residual-based goodness-of-fit (A), bivariate normality (B), influence and outlier detection analyses (C
and D, respectively).
Figure 10 Summary ROC plot of SEN and SPE of CTCs detection in stage I to III, and IV gastric cancer patients. (Dotted ellipses around
the spots represent the 95% CI around the summary estimates. The diamonds and rectangles and circles represent individual studies and size of
the diamonds/rectangles is proportional to the number of patients included in the study).
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http://www.biomedcentral.com/1471-2407/13/314language publications which are not included in our sys-
tematic review, such as German or Japanese literatures.
According to the included studies in this systematic re-
view, it is easy found that nearly all of the patients and
controls were Asians, so the clinical significance may have
its limitation. More studies about Caucasians are needed
to explore the diagnostic value of CTCs detection.
Finally, although we search for studies without the
limitation of time and languages, we didn’t search for
unpublished data. Diagnostic studies are easy to under-
take and are not usually recorded on research registries,
so it is difficult for researchers to search for unpublished
data. Therefore, some missing and unpublished data
may not be included in current study, which may over-
estimate the pooled results.
Conclusions
In summary, with lower and inconsistent SEN estimates
for CTCs detection in GC, CTCs detection alone can-
not be recommended as a screening test of GC. How-
ever, it might be used as a noninvasive method for the
confirmation of the gastric cancer diagnosis because of
the high SPE.
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